Generic Therapy Launched for Metastatic NSCLC and Pancreatic Cancer – Drug for nerve pain boosts high for opioid abusers.

16511-pharmacy-board-standard-041216Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

Generic Therapy Launched for Metastatic NSCLC and Pancreatic Cancer – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg, and the product has been launched in the United States market. This product is a generic version of Genentech’s Tarceva.

Erlotinib hydrochloride tablets are indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least 1 prior chemotherapy regimen.

CLICK HERE FOR CONTINUE READING

This entry was posted in Pharmacist and tagged , , , . Bookmark the permalink.

Comments are closed.